Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
0.05% cyclosporine eye drops vs 0.1% tacrolimus for chronic ocular GVHD
ChiCTR2100054899Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Jan 2021
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label trial of cyclosporine and tacrolimus in graft-versus-host disease (GVHD) (2 arms), sponsored by Peking University Third Hospital. Primary endpoints: Visual acuity, Intraocular pressure and 5 more. Started Jan 2021; status: recruiting.
02
Drugs
cyclosporinetacrolimus
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on ChiCTR2100054899.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054899.